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ABSTRACT: Mental retardation affects 2-3% of the population and shows a high heritability. 
Neurodevelopmental disorders that include pronounced impairment in language and speech skills 
occur less frequently. For most cases, the molecular basis of mental retardation with or without 
speech and language disorder is unknown due to the heterogeneity of underlying genetic factors. 
We have used molecular karyotyping on 1523 patients with mental retardation to detect copy 
number variations (CNVs) including deletions or duplications. These studies revealed three 
heterozygous overlapping deletions solely affecting the forkhead box P1 (FOXP1) gene. All three 
patients had moderate mental retardation and significant language and speech deficits. Since our 
results are consistent with a de novo occurrence of these deletions, we considered them as causal 
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although we detected a single large deletion including FOXP1 and additional genes in 4104 
ancestrally matched controls. These findings are of interest with regard to the structural and 
functional relationship between FOXP1 and FOXP2. Mutations in FOXP2 have been previously 
related to monogenic cases of developmental verbal dyspraxia. Both FOXP1 and FOXP2 are 
expressed in songbird and human brain regions that are important for the developmental processes 
that culminate in speech and language. ©2010 Wiley-Liss, Inc. 
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INTRODUCTION 
Mental retardation (MR) is defined as a significant impairment of cognitive and adaptive functions with an 
onset before the age of 18 years (Ropers, 2008). Based on the assessment of patients’ intelligence quotients (IQs), 
MR is usually classified into mild (IQ 50-70), moderate (IQ > 35) and severe (IQ > 20) forms. It has been shown 
that the causes of the disorder include environmental and genetic factors (Inlow and Restifo, 2004), still for most 
cases, the pathological basis remains unexplained. The high degree of heritability of MR is highlighted by the 
estimation that up to 50% of severe cases are caused by genetic abnormalities (Inlow and Restifo, 2004). Due to 
the heterogeneity of the underlying genetic factors, the identification of MR candidate genes still remains difficult 
to date. A promising approach to detect small chromosomal copy number variants (CNVs) in the genome is the use 
of molecular karyotyping techniques (Marshall, et al., 2008). CNVs have been shown as the underlying cause or 
susceptibility factors for a variety of autism spectrum disorders and conditions associated with MR (Berkel, et al., 
2010; Marshall, et al., 2008; Sebat, et al., 2007; Zweier, et al., 2010). Array-based comparative genomic 
hybridization has also enabled the detection of interstitial submicroscopic copy number alterations in about 10 % 
of patients with MR (de Vries, et al., 2005). Here we present the identification of overlapping heterozygous 
deletions affecting the FOXP1 (MIM# 605515) gene in three unrelated patients with MR and significant speech 
and language disorder. 
 
MATERIALS AND METHODS 
Oligonucleotide arrays 
CNV data were generated in different institutions within the MRNET consortium (Supp. Table S1). Patient 1 
was part of a cohort of 387 patients investigated with Infinium Human550-Quad and Human610-Quad arrays 
(Illumina). Intensity data were normalized as described previously (Wagenstaller, et al., 2007). Segmentation was 
performed with circular binary segmentation as implemented in the R-package ‘DNAcopy’. Patient 2 was part of a 
cohort of 188 patients investigated using whole genome oligonucleotide 244K arrays (Agilent Technologies, Santa 
Clara, CA). Image data were analyzed using Feature Extraction 9.5.3.1 and CGH Analytics 3.4.40 software 
(Agilent Technologies, Santa Clara, CA) with the following analysis settings: aberration algorithm ADM-2; 
threshold: 6.0; window size: 0.2 Mb; filter: 5probes, log2ratio = 0.29. Patient 3 belonged to a cohort of 184 
patients analyzed with genome-wide human SNP 6.0 arrays (Affymetrix, Santa Clara, CA). Analysis of data was 
performed using the Genotyping Console Software 3.0 (Affymetrix). For the detection of genomic deletions and 
duplications, automated analysis by Segment Reporting Tools was used. Regions showing at least 5-10 aberrant 
neighboring SNPs / markers and having a size of at least 100 kb were classified as being significant. Additional 
CNV data of 764 MR patients from other institutions not listed here were obtained through the database of the 
MRNET (www.german-mrnet.de).  
Control populations 
Controls consisted of 1146 individuals from popgen, 813 individuals of a population-based cohort (KORA 
study), 972 patients with cardiac ischemia (AGNES study), 482 patients with early-onset lung cancer (LUCY 
study), and 691 long-lived individuals (LLI study). FOXP1 Deletions  E1853 
 
Breakpoint identification 
PCR reactions on genomic DNA level were performed to amplify the junction fragments that spanning the 
telomeric and centromeric breakpoints. Fragments were directly sequenced with the respective forward and reverse 
primer: B35_FOXP1F/B8_FOXP1R (patient 1): 5'-atgctgaaggtggaatggg-3', 5'-ggccacatacgtgttgtcag-3'; 
O06_for/Z02_rev (patient 2): 5'-cgttgccagctcaaggttat-3', 5'-taagtgtgtgcgaagccaag-3'; bp_FOXP1_3for/rev (patient 
3): 5'-gcacctgaccctctagctca-3', 5'-ggttcagccactggtctttc-3'. 
Fluorescence in situ hybridization (FISH) 
Preparation of chromosome metaphases of patient 3 and his parents and FISH were performed according to 
standard protocols using BAC DNA probes RP11-215K24, RP11-154H23, CTD-3121O8 (Invitrogen, Darmstadt, 
Germany) and RP11-788D09 (BACPAC Resource Center, Oakland, USA). 
Mutation screening 
FOXP1 (NM_032682.4) exons were PCR amplified using intronic primers and investigated with 2 different 
methods: 197 DNAs were investigated by direct sequencing, 772 DNAs were analyzed using dye-binding/high-
resolution DNA melting point analysis (LightScanner HR I 384, Idaho Technology). Genotyping of the controls 
were performed on a MALDI-TOF mass-spectrometer (Sequenom MassArray system) using the homogeneous 
mass-extension (hME) process for producing primer extension products. Primers were designed with ExonPrimer 
(http://ihg.helmholtz-muenchen.de/ihg/ExonPrimer.html)  and are available on request. Nucleotide numbering 
reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon. 
SLIC study 
The SLIC probands were selected from samples ascertained by the Newcomen Centre at Guys Hospital and by 
the Manchester Language Study (The SLI Consortium, 2002) and all had severe language impairments with 
language skills more than 1.5 SD below the normative mean for their chronological age in combination with full 
IQ scores at least 0.7 SD below that expected for their age. IQ scores are derived from the Wechsler Intelligence 
Scales for Children (WISC-III). The 46 (16 males, 30 females; average age: 11 years and 3 months) individuals 
would not meet strict SLI diagnostic criteria as individuals with IQ problems are usually excluded. Nonetheless all 
probands had severe language impairments which require special schooling arrangements and continued support. 
 
RESULTS 
FOXP1 deletions 
In a collaborative effort we performed a genome-wide microarray scan for CNVs in a German cohort of 1523 
unrelated patients with unexplained mental retardation. Standard diagnostic tests like chromosomal karyotyping, 
fragile X testing and subtelomeric screenings were performed in most cases to rule out known causes of MR. The 
recruitment of patients was part of the German Mental Retardation Network (MRNET) study. Approval for the 
study was obtained by the ethical review boards of the participating institutions and informed written consent was 
obtained from all participants.  
Copy number analysis revealed overlapping deletions at chromosome 3p14.1 affecting solely the FOXP1 gene 
in three unrelated cases, two males and one female aged between 5.5 to 7 years. Deletion sizes of 498 kb, 659 kb 
and 1047 kb included all but the first of the coding exons in patient 1 (Wagenstaller, et al., 2007) and the entire 
coding region in the other two patients 2 and 3 (Figure 1A). The deletions were verified by fluorescence in situ 
hybridization (FISH; Figure 1B) or quantitative real-time PCR (data not shown). DNA analysis of the unaffected 
parents by molecular karyotyping and FISH indicated that patients 2 and 3 carried de novo deletions, while it could 
only be shown that the mother of patient 1 does not carry the deletion since the father was not available for 
investigation. We found that the deleted alleles were of paternal origin in all three patients. Sequencing of the 
coding exons of the remaining FOXP1 allele did not reveal any sequence variation compared to the annotated 
reference sequence (NM_032682). Characterization of the breakpoints was achieved by amplification and 
sequencing of the respective junction fragments (GenBank EF504249, HM124444, and GU980955; Figure 1C). E1854  Horn et al. 
For the deletion in patient 1, the distal breakpoint is located within a long interspersed nuclear element (LINE) 
repeat (L1/L1PA5) while the proximal breakpoint lies in a MER1-type repeat (MER58A). No repetitive sequences 
are present at the breakpoint loci in patient 2, however, microhomoloy of 3 bases (AGA) is observed at the 
breakpoints. The distal breakpoint of the deletion in patient 3 is located in a short interspersed nuclear element 
(SINE) while repetitive sequences are missing at the proximal breakpoint. The absence of homologous regions at 
the breakpoints suggests that the deletions were likely generated by double-strand breaks and non-homologous 
end-joining.  
 
Control populations 
To assess the significance of these findings, we checked the FOXP1 region for CNVs in the Database of 
Genomic Variants (DGV) (Iafrate, et al., 2004) and in 4104 ancestrally matched controls which have been 
investigated with different types of high-density SNP arrays containing at least 500,000 SNPs (Supp. Table S1). 
No CNVs affecting the coding region were found in the DGV database. Copy number analysis in the 4104 control 
individuals revealed the presence of a single large 3p14.1p13 deletion of approximately 1.3 Mb affecting FOXP1, 
EIF4E3 (MIM# 609896), PROK2 (MIM# 607002) and GPR27 (MIM# 605187) in an individual of the LLI study, 
with no indications of a comparable MR phenotype. Detailed clinical data on intellectual abilities were lacking and 
 
 
 
Figure 1. FOXP1 deletions in patients with MR. 
(A) Schematic presentation of the position and size of 
the deleted regions (grey bars) at chromosome 3p14.1 in 
three patients with MR and in a control individual. Only 
the  FOXP1  gene (NM_032682, minus strand) is 
affected. The coding exons are indicated by larger 
vertical lines compared to the non-coding exons.  
(B) Results of fluorescence in situ hybridization (FISH) 
shown for patient 3 and his parents. The positions of the 
BAC clones RP11-215K24 and RP11-154H23 flanking 
the deletion, as well as CTD-3121O8 located within the 
deletion (green signals) are given in Figure 1A. BAC 
clone RP11-778D09 was used as a reference probe 
located on chromosome 3q27 (red signals). The white 
arrow indicates the missing signal for clone CTD-
3121O8 on one of the patient’s chromosomes 3 while 
the signal is present in both chromosomes of the parents.  
(C) Breakpoint characterization by sequencing of 
junction fragments amplified by PCR on genomic DNA 
of the patients.  
In patient 1, the distal breakpoint was located at position 
70,807,767, the proximal breakpoint at position 
71,305,965 with a deletion size of 498,198 bp. In patient 
2, the two breakpoints were located within a 
microhomology of three nucleotides (AGA) at the 
telomeric side at position 70,778,067-70,778,070 and the 
centromeric side at 71,437,354-71,437,357 resulting in a 
deletion size of 659,287 bp. For patient 3, the telomeric 
breakpoint is located at position 70,341,246-70,341,247 
and the centromeric breakpoint at position 71,388,173–
71,388,174 with a deletion size of 1,046,927 bp. All 
positions are given according to hg18, UCSC Human 
Genome March 2006. FOXP1 Deletions  E1855 
 
further investigations not possible due to the design of the study. In particular, we could not investigate the 
presence of somatic mosaicism. Application of Fisher's exact test on these data, not considering the controls 
contained in the DGV database, resulted in a nominal p-value of 0.06. Thus, although the absence of deletions in 
the unaffected parents is consistent with a role of FOXP1 in the clinical findings of the patients incomplete 
penetrance of deletions in this chromosomal interval cannot be ruled out. 
Speech and language development 
Detailed clinical investigation of the three patients revealed that they present moderate MR in combination with 
a general developmental delay (Table 1). In all patients, the non-verbal IQ score was assessed as ≤ 50 (3 SD below 
the mean). Speech and language development was estimated in the same range. All three patients started to speak 
at age of 3.5 years and used only combinations of two words at ages 5, 5.5 and 7 years, respectively. In all patients, 
the productive and receptive vocabulary came up to less than 100 words. Expressive language was more affected 
than receptive abilities. Dysgrammatism and very poor speech articulation with difficulties producing consonants 
at the beginning of words was present in all patients. Two showed oromotoric problems including difficulties with 
lip protrusion. In infancy, patients had a tendency to keep their mouth open and patient 2 suffered from swallowing 
difficulties. In addition, all showed considerably retarded gross-motor development with unsupported walking as 
late as 24 to 36 months. Brain magnetic resonance imaging and electroencephalography did not reveal any 
abnormalities. None of the patients showed sensorineural hearing loss. Ophthalmologic testing disclosed moderate 
myopia only in patient 1. Upon physical examinations, normal growth parameters regarding height and 
occipitofrontal head circumference were documented for two patients but presence of obesity was striking in both. 
Consistent craniofacial anomalies seen in patients 2 and 3 included broad and prominent forehead and frontal hair 
upsweep (Figure 2). 
 
Table 1. Clinical description of FOXP1 deletion patients 
  Patient 1  Patient 2  Patient 3  
General features     
Age of last assessment  7 years  5.5 years  6 years 
Sex Male  Female  Male 
Occipitofrontal head circumference 
(SD) 
+1.2 +0.8 +1.3 
 
 
Height (SD)  +1.4  +0.6  -0.4 
Weight (SD)  +0.5  +2.7  +2.5 
Facial gestalt  no dysmorphisms  Prominent forehead, 
frontal hair upsweep 
Prominent forehead, 
frontal hair upsweep 
Non-verbal performance IQ  < 50  < 50  50 
Gross motor delay  +  +  + 
Age at sitting  n.d.  12 months  8 months 
Age at walking  24 months  36 months  24 months 
Swallowing difficulties  n.d.  +  - 
Oromotor problems 
(e.g. lip protrusion, tongue elevation)  + +  - 
Speech and language development       
First vocalizing at age of  n.d.  4 months  12 months 
First words at age of  3.5 years  3.5 years  3.5 years 
Combined words at age of  7 years  5 years  5.5 years 
Articulation problems   +  +  + 
Poor grammar  +  +  + 
n.d., not documented 
 
FOXP1 point mutations 
In order to detect possible FOXP1 point mutations, we sequenced the coding exons in 883 patients with MR 
from the MRNET database and discovered eight different non-synonymous, three synonymous and nine non-E1856  Horn et al. 
coding variants (Table 2). All variants were genotyped in up to 676 unrelated healthy controls. Three of the 
identified coding variants, p.Ser5Pro, p.Pro215Ala and p.Thr390Ser were also present at similar frequencies in 
healthy matched controls, but none of the coding variants was found in the HapMap or the NCBI dbSNP database. 
Five of the non-synonymous variants were transmitted through an apparently unaffected parent; for the other 
variants, heredity could not be established as either one or both parents were not available (Table 2). Variants 
transmitted by an unaffected parent are usually classified as non-pathogenic. Still, presuming a multigenic 
threshold model for MR, disease relevance cannot be completely ruled out. To uncover the neurobiological 
significance of these variants, investigation of the functional effects of the putative mutations is needed. 
Since the core phenotype of the three patients carrying FOXP1 deletions consisted of MR with significant 
speech and language deficits, we additionally sequenced FOXP1 coding exons in DNA of 40 patients with a 
tentative diagnosis of Angelman syndrome (without microcephaly and negative for SNRPN imprinting). We also 
sequenced the DNA of 46 probands from the Specific Language Impairment Consortium (SLIC) collection (The 
SLI Consortium, 2002). For both groups, no sequence variants in the coding region of FOXP1 were detected. 
 
Table 2. Summary of FOXP1 variants identified in controls and in patients with mental retardation 
Variants 
 
MR patients  Controls 
Genotypes  Genotypes  Status of inheritance 
     11 12  22    11 12 22 
Non-synonymous variants            
c.13T>C    p.Ser5Pro  Exon  6  882 1  0  maternal  674 2  0 
c.226_228dupCAG   p.Gln76dup  Exon 7  882  1  0  maternal  676  0  0 
c.301A>G  p.Met101Val Exon  8  882 1  0  n.a.  667 0  0 
c.643C>G
†  p.Pro215Ala Exon  10 882 1  0  maternal  336 2  0 
c.781T>C    p.Ser261Pro  Exon  11 882 1  0  n.a.  676 0  0 
c.1168A>T    p.Thr390Ser  Exon  15 882 1  0  maternal  675 1  0 
c.1709A>G    p.Asn570Ser Exon  19 882 1  0  paternal  338 0  0 
c.1790A>C    p.Asn597Thr Exon  20 882 1  0  n.a.  676 0  0 
Synonymous variants             
c.768G>A    p.Thr256Thr Exon  11 882 1  0  n.a.  673 0  0 
c.1188G>A    p.Ser396Ser  Exon  15 882 1  0  maternal  674 0  0 
c.1515C>T    p.Asn505Asn  Exon  17 882 1  0  maternal  674 0  0 
Non-coding variants            
c.1-5G>A    5’UTR  882 1  0  paternal  674 0  0 
c.180+49T>C    Intron 6   80  30  1  not tested (dbSNP rs2037474) 
c.181-29G>A
†    Intron 6  875  7  1  1 x mat, 2 x pat, 
1 x mat + pat, 4 x n.a. 
653 21  0 
c.181-30C>T    Intron  6  882 1  0  n.a.  676 0  0 
c.664+11A>G    Intron  10  882 1  0  maternal  674 0  0 
c.664+6C>T    Intron  10  882 1  0  n.a.  674 0  0 
c.975-14A>G    Intron  12  882 1  0  maternal  673 1  0 
c.1889+20A>C
†    Intron 20  95  15  1  not tested (dbSNP rs7638391) 
c.1890-15G>T
†    Intron 20  110  1  0  not tested (dbSNP rs7639736) 
Listed is the number of individuals carrying the respective homozygous or heterozygous genotypes (11, 12 or 22; GenBank NM_032682.4). 
Patients and matched healthy controls were of German origin. 
†also found by Vernes et al, 2009. MR, mental retardation; n.a., parents not 
available; mat, maternal; pat, paternal. Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG 
translation initiation codon. 
 
DISCUSSION 
This is the first report of 3p14.1 deletions that solely affect the FOXP1 gene in three unrelated patients with 
moderate mental retardation in combination with a significant impairment of speech and language abilities. We 
investigated a large control population and the apparent finding of a large 3p14.1p13 deletion in this cohort 
affecting FOXP1 and further genes illustrates the difficulties to assess the significance of rare mutational events in 
extremely heterogeneous diseases and may point to incomplete penetrance. The additional findings of obesity and 
mild craniofacial anomalies (prominent forehead and frontal hair upsweep) in two patients might be part of the FOXP1 Deletions  E1857 
 
clinical spectrum associated with FOXP1 deletions. A de novo deletion of this chromosomal interval on 3p14.1p13 
affecting part of FOXP1 and three additional genes (EIF4E3, PROK2 and GPR27) has been previously described 
in a boy with multiple abnormalities including speech and developmental delay (Pariani, et al., 2009). Compared 
to the clinical findings in our patients, there is a clear overlap with regard to the speech and developmental delay 
suggesting that haploinsufficiency of FOXP1 is indeed causative for this phenotype. As our patients did not show 
any of the other clinical signs like contractures, hypertonia and blepharophimosis, present in the boy carrying the 
larger 3p14.1p13 deletion (Pariani, et al., 2009), these might rather be caused by the haploinsufficiency of the 
additionally affected genes.  
FOXP1 belongs to a functionally diverse family of forkhead box (FOX) transcription factors that are all 
characterized by a highly conserved FOX domain. FOX genes have been shown to play important roles in diverse 
cellular functions including metabolic and developmental processes (Carlsson and Mahlapuu, 2002). While the 
function of FOXP1 during blood cell, lung and heart formation has already been addressed (Hu, et al., 2006; Shi, 
et al., 2004; Shu, et al., 2001; Wang, et al., 2004), the role of FOXP1 in neuronal processes, in particular brain 
development, is still unclear. In a mouse mutant model, Foxp1 has recently been shown to be an important 
accessory factor in Hox transcriptional output, thus regulating motor neuron diversification and connectivity to 
target muscles (Dasen, et al., 
2008; Rousso, et al., 2008). 
These findings are of particular 
interest with regard to the gross-
motor and oromotor deficits seen 
in our patients with FOXP1 
deletions.  
Currently, four FOX genes 
(FOXC1  [MIM# 601090], 
FOXC2  [MIM# 602402], 
FOXP2 [MIM# 605317] and 
FOXP3  [MIM# 300292]) are 
listed in the Online Mendelian 
Inheritance in Man (OMIM) 
database that have been shown 
to be causative for human 
diseases (Hannenhalli and 
Kaestner, 2009). With regard to 
structure and expression profiles, 
the most interesting gene related 
to  FOXP1 is FOXP2. Rare 
mutations of FOXP2 have been 
described in individuals having 
expressive and receptive 
language and speech deficits generally described as developmental verbal dyspraxia (Hurst, et al., 1990; Lai, et al., 
2001; MacDermot, et al., 2005; Marshall, et al., 2008). It is striking, that patients with FOXP1 deletions show a 
comparable speech and language deficit. Most of the mutations affecting FOXP2 are deletions and maternal 
uniparental disomies. In almost all cases, the affected allele is of paternal origin suggesting differential parent-of-
origin expression of FOXP2 in human speech development (Marshall, et al., 2008). Of note, there is some 
parallelism as the three FOXP1 deletions we describe are also of paternal origin. 
A functional relationship between Foxp1 and Foxp2 has been previously demonstrated in mouse, as they form 
homo- and heteromers necessary for efficient DNA binding (Marshall, et al., 2008). FoxP1 and FoxP2 also show 
overlapping expression patterns within brains of zebra finches and fetal human brains, particularly in subcortical 
regions that play important roles in sensorimotor integration and coordinated movements important for 
vocalization and speech respectively (Teramitsu, et al., 2004). From these findings it was speculated that FOXP1 
might play an important role in the development of brain circuits that coordinate fine sequential motor control 
required for articulation. 
 
 
Figure 2. Facial Phenotype of patients 2 and 3 
Consistent facial features of patients showing broad and prominent forehead, 
frontal hair upsweep, and a short nose. (A) Patient 2, at the age of 4 years and 3 
months. (B) Patient 3, at the age of 6 years, had in addition sparse lateral eye 
brows and down-slanting palpebral fissures.  
 
 
 
Figure 2. Facial Phenotype of patients 2 and 3. Consistent facial features of 
patients showing broad and prominent forehead, frontal hair upsweep, and a short 
nose. (A) Patient 2, at the age of 4 years and 3 months. (B) Patient 3, at the age of 
6 years, had in addition sparse lateral eye brows and down-slanting palpebral 
fissures.  
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Although the mean non-verbal IQ of the members of the large family carrying FOXP2 mutation was lower than 
of the unaffected members, non-verbal intellectual impairment could not be considered characteristic of the 
phenotype associated with this FOXP2 mutation (Lai, et al., 2001). This is in contrast to the clinical findings in our 
patients with FOXP1 deletions who, in addition to their speech and language disabilities, exhibit significantly 
reduced non-verbal IQ scores. This may indicate that additional distinct functions of FOXP1 exist, presumably 
acting on a more global level in neuronal development compared to FOXP2. This would be in line with results 
from a previous study on 49 patients with developmental verbal dyspraxia and normal intelligence, where no 
causative FOXP1 mutations could be detected (Vernes, et al., 2009).  
In conclusion, we report a previously unknown cause of MR associated with significant speech and language 
disorder defined by FOXP1 deletions. We propose that haploinsufficiency of FOXP1 leads to abnormal 
development of neural structures that coordinate general cognitive and psychomotoric as well as verbal abilities. 
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Supp. Table S1. Setup of molecular karyotyping analyses in patients with MR and control individuals 
Cohort  Arrays  Data analysis; thresholds / settings  Individuals 
Patients MRNET 
Munich  Infinium Human550-Quad and Human610-Quad 
(Illumina) 
Data were normalized according to Wagenstaller et al. (2007). 
Segmentation was performed with circular binary segmentation as 
implemented in the R-package ‘DNAcopy’. 
387 
Berlin  Whole-genome oligonucleotide 244K array 
(Agilent Technologies, Santa Clara, CA) 
Feature Extraction 9.5.3.1 and CGH Analytics 3.4.40; aberration 
algorithm ADM-2, threshold: 6.0; window size: 0.2 Mb; filter: 5 
probes; log2ratio = 0.29 
188 
 
Heidelberg  Genome-wide human SNP Array 6.0  
(Affymetrix, Santa Clara, CA) 
Segment Reporting Tools of the Genotyping Console 3.0 
software; only CNVs > 100 kb with at least 5-10 aberrant SNPs   184 
Other*     764 
Sum     1523 
Control individuals 
popgen study  Genome-wide human SNP Array 6.0  
(Affymetrix, Santa Clara, CA)  CNVineta (www.ikmb.uni-kiel.de/cnvineta) 1146 
KORA study  Infinium Human550-Quad (Illumina)  Data  were  normalized according to Wagenstaller et al. (2007). 
Segmentation was performed with circular binary segmentation as 
implemented in the R-package ‘DNAcopy’. 
813 
AGNES study  Infinium Human6100-Quad (Illumina)  972 
LUCY study  Infinium Human550-Quad (Illumina)  482 
LLI study  Genome-wide human SNP Array 6.0  
(Affymetrix, Santa Clara, CA)  CNVineta (www.ikmb.uni-kiel.de/cnvineta) 691 
Sum     4104 
Given are the setups of the molecular karyotyping performed in MR patients by the authors’ institutions. *Additional CNV data of MR patients from 
other institutions (not listed here) were obtained through the database of the MRNET (www.german-mrnet.de); popgen study (www.popgen.de); KORA 
study (www.helmholtz-muenchen.de/kora); MR, mental retardation. 
 